Scinai expects operating runway through late 2027
SCNI•Scinai Immunotherapeutics expects its operating runway to extend through late 2027, supported by approximately $5.3 million in recent net financing proceeds and expected customer payments. Activating later CDMO project phases could extend runway into the third quarter of 2028, subject to sales, collections and execution.
1. Runway and financing
Scinai Immunotherapeutics expects operating runway through late 2027, supported by recent financing and expected customer payments. Recent equity financing generated approximately $5.3 million in combined net proceeds, excluding future exercises of newly issued warrants.
2. CDMO payments
A CDMO agreement includes approximately $5.1 million in committed base service fees, expected to contribute revenue during 2026 and 2027. Additional uncommitted clinical manufacturing carries indicative service fees of approximately $5.85 million for late 2027 and the first half of 2028; activation and delivery of later project phases could extend runway into the third quarter of 2028, subject to sales, collections and execution.
